BACKGROUND: Antibodies against phospholipase A2 receptor 1 (PLA2R1) are found in 80% of patients with membranous nephropathy, and previous studies described three autoantibody-targeted PLA2R1 epitope regions. Although anti-PLA2R1 antibody levels are closely associated with treatment response and disease prognosis, the clinical role of epitope regions targeted by autoantibodies is unclear. METHODS: In a prospective cohort of 150 patients with newly diagnosed PLA2R1-associated membranous nephropathy, we investigated the clinical role of epitope-recognition patterns and domain-specific PLA2R1 antibody levels by western blot and ELISA. RESULTS: We identified a fourth epitope region in the CTLD8 domain of PLA2R1, which was recognized by anti-PLA2R1 antibodies in 24 (16.0%) patients. In all study patients, anti-PLA2R1 antibodies bound both the N-terminal (CysR-FnII-CTLD1) region and the C-terminal (CTLD7-CTLD8) region of PLA2R1 at study enrollment. The total anti-PLA2R1 antibody levels of patients determined detection of domain-specific PLA2R1 antibodies, and thereby epitope-recognition patterns. A remission of proteinuria occurred in 133 (89%) patients and was not dependent on the domain-recognition profiles. A newly developed ELISA showed that domain-specific PLA2R1 antibody levels targeting CysR, CTLD1, and CTLD7 strongly correlate with the total anti-PLA2R1 antibody level (Spearman's rho, 0.95, 0.64, and 0.40; P<0.001, P<0.001, and P=0.002, respectively) but do not predict disease outcome independently of total anti-PLA2R1 antibody levels. CONCLUSIONS: All patients with PLA2R1-associated membranous nephropathy recognize at least two epitope regions in the N- and C-terminals of PLA2R1 at diagnosis, contradicting the hypothesis that PLA2R1 "epitope spreading" determines the prognosis of membranous nephropathy. Total anti-PLA2R1 antibody levels, but not the epitope-recognition profiles at the time of diagnosis, are relevant for the clinical outcome of patients with this disease.
BACKGROUND: Antibodies against n class="Gene">phospholipase A2 receptor 1 (PLA2R1) are found in 80% of patients with membranous nephropathy, and previous studies described three autoantibody-targeted PLA2R1 epitope regions. Although anti-PLA2R1 antibody levels are closely associated with treatment response and disease prognosis, the clinical role of epitope regions targeted by autoantibodies is unclear. METHODS: In a prospective cohort of 150 patients with newly diagnosed PLA2R1-associated membranous nephropathy, we investigated the clinical role of epitope-recognition patterns and domain-specific PLA2R1 antibody levels by western blot and ELISA. RESULTS: We identified a fourth epitope region in the CTLD8 domain of PLA2R1, which was recognized by anti-PLA2R1 antibodies in 24 (16.0%) patients. In all study patients, anti-PLA2R1 antibodies bound both the N-terminal (CysR-FnII-CTLD1) region and the C-terminal (CTLD7-CTLD8) region of PLA2R1 at study enrollment. The total anti-PLA2R1 antibody levels of patients determined detection of domain-specific PLA2R1 antibodies, and thereby epitope-recognition patterns. A remission of proteinuria occurred in 133 (89%) patients and was not dependent on the domain-recognition profiles. A newly developed ELISA showed that domain-specific PLA2R1 antibody levels targeting CysR, CTLD1, and CTLD7 strongly correlate with the total anti-PLA2R1 antibody level (Spearman's rho, 0.95, 0.64, and 0.40; P<0.001, P<0.001, and P=0.002, respectively) but do not predict disease outcome independently of total anti-PLA2R1 antibody levels. CONCLUSIONS: All patients with PLA2R1-associated membranous nephropathy recognize at least two epitope regions in the N- and C-terminals of PLA2R1 at diagnosis, contradicting the hypothesis that PLA2R1 "epitope spreading" determines the prognosis of membranous nephropathy. Total anti-PLA2R1 antibody levels, but not the epitope-recognition profiles at the time of diagnosis, are relevant for the clinical outcome of patients with this disease.
Authors: Jue Zhang; Jane Carter; Sophia Siu; Jason W O'Neill; Andrew H Gates; John Delaney; Christopher Mehlin Journal: Curr Pharm Biotechnol Date: 2010-04 Impact factor: 2.837
Authors: Cornelia Dähnrich; Lars Komorowski; Christian Probst; Barbara Seitz-Polski; Vincent Esnault; Jack F Wetzels; Julia M Hofstra; Elion Hoxha; Rolf A Stahl; Gérard Lambeau; Winfried Stöcker; Wolfgang Schlumberger Journal: Clin Chim Acta Date: 2013-03-27 Impact factor: 3.786
Authors: Jane Carter; Jue Zhang; Thien-Lan Dang; Haruki Hasegawa; Janet D Cheng; Irene Gianan; Jason W O'Neill; Martin Wolfson; Sophia Siu; Sheldon Qu; David Meininger; Helen Kim; John Delaney; Christopher Mehlin Journal: Protein Sci Date: 2010-02 Impact factor: 6.725
Authors: Julia M Hofstra; Hanna Debiec; Colin D Short; Timotheé Pellé; Robert Kleta; Peter W Mathieson; Pierre Ronco; Paul E Brenchley; Jack F Wetzels Journal: J Am Soc Nephrol Date: 2012-09-06 Impact factor: 10.121
Authors: Volker Jäger; Konrad Büssow; Andreas Wagner; Susanne Weber; Michael Hust; André Frenzel; Thomas Schirrmann Journal: BMC Biotechnol Date: 2013-06-26 Impact factor: 2.563
Authors: Franziska von Haxthausen; Linda Reinhard; Hans O Pinnschmidt; Michael Rink; Armin Soave; Elion Hoxha; Rolf A K Stahl Journal: Front Immunol Date: 2018-12-20 Impact factor: 7.561
Authors: Barbara Seitz-Polski; Hanna Debiec; Alexandra Rousseau; Karine Dahan; Christelle Zaghrini; Christine Payré; Vincent L M Esnault; Gérard Lambeau; Pierre Ronco Journal: J Am Soc Nephrol Date: 2017-11-07 Impact factor: 10.121
Authors: Maryline Fresquet; Thomas A Jowitt; Jennet Gummadova; Richard Collins; Ronan O'Cualain; Edward A McKenzie; Rachel Lennon; Paul E Brenchley Journal: J Am Soc Nephrol Date: 2014-10-06 Impact factor: 10.121
Authors: Maxime Teisseyre; Marion Cremoni; Sonia Boyer-Suavet; Caroline Ruetsch; Daisy Graça; Vincent L M Esnault; Vesna Brglez; Barbara Seitz-Polski Journal: Front Immunol Date: 2022-05-04 Impact factor: 8.786
Authors: Gian Marco Ghiggeri; Barbara Seitz-Polski; Joana Justino; Christelle Zaghrini; Christine Payré; Vesna Brglez; Guillaume Dolla; Alberto Sinico; Francesco Scolari; Augusto Vaglio; Marco Prunotto; Giovanni Candiano; Antonella Radice; Maurizio Bruschi; Gérard Lambeau Journal: Clin J Am Soc Nephrol Date: 2020-11-30 Impact factor: 8.237
Authors: Philipp Gauckler; Jae Il Shin; Federico Alberici; Vincent Audard; Annette Bruchfeld; Martin Busch; Chee Kay Cheung; Matija Crnogorac; Elisa Delbarba; Kathrin Eller; Stanislas Faguer; Kresimir Galesic; Siân Griffin; Martijn W F van den Hoogen; Zdenka Hrušková; Anushya Jeyabalan; Alexandre Karras; Catherine King; Harbir Singh Kohli; Gert Mayer; Rutger Maas; Masahiro Muto; Sergey Moiseev; Balazs Odler; Ruth J Pepper; Luis F Quintana; Jai Radhakrishnan; Raja Ramachandran; Alan D Salama; Ulf Schönermarck; Mårten Segelmark; Lee Smith; Vladimír Tesař; Jack Wetzels; Lisa Willcocks; Martin Windpessl; Ladan Zand; Reza Zonozi; Andreas Kronbichler Journal: Kidney Int Rep Date: 2021-01-13
Authors: Anne-Els van de Logt; Joana Justino; Coralien H Vink; Jan van den Brand; Hanna Debiec; Gérard Lambeau; Jack F Wetzels Journal: Kidney Int Rep Date: 2021-04-22